Notice Regarding Revision to Year-End Dividend Forecast (Increase)
Filed with TSE · · 1 page · English
Summary by 6ix AI
Zeria Pharmaceutical Co., Ltd. has announced a revision to its year-end dividend forecast, increasing it from a previous amount to a new amount per share. The company emphasizes returning profits to shareholders as a key management priority and aims for stable and continuous dividends. The increase in the dividend reflects the company's performance up to the second quarter and other relevant factors.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zeria Pharmaceutical Co., Ltd. on 6ix
Earlier from Zeria Pharmaceutical
- Notice Concerning Acquisition of Equity Interests of Haupt Pharma Wulfling GmbH (Making It a Sub-subsidiary) by a Consolidated Subsidiary
- [Updated]Consolidated Financial Results for the First Three Months of the Fiscal Year Ending March 31, 2027[Under Japanese GAAP]
- [Summary] Financial Results for the First Three Months of the Fiscal Year Ending March 31,2027
- 70th Business Report (From April 1, 2023 to March 31, 2024.)
- 69th Business Report (From April 1, 2022 to March 31, 2023.)
Follow Zeria Pharmaceutical into a list and get an email when it puts out news.
Follow Zeria Pharmaceutical